PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock (NCT04107402) | Clinical Trial Compass
CompletedNot Applicable
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock
Belgium150 participantsStarted 2019-03-15
Plain-language summary
Knowing the dramatic increase in thrombin generation during sepsis, our research hypothesis is that AMPK-induced ACC phosphorylation in platelets is increased and that this might modulate platelets metabolism and more particularly platelets inflammatory mediators content, coming from AA and lipids.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed consent of patients, their relatives or independent physician
* Septic shock defined as a sepsis with vasopressor therapy needed to elevate MAP ≥65 mmHg, and lactate \> 2 mmol/L, despite adequate fluid resuscitation of 30mL/kg of intravenous crystalloid within 6 hours. Inclusion within 48 hours of ICU admission.
* Covid-19 patients with ARDS and PaO2/FiO2 \< 200. Inclusion within 5 days after ICU admission.
Exclusion Criteria:
* Patients on therapeutic anticoagulation therapy (oral or parenteral) including heparins, fondaparinux, vitamin K antagonist, novel oral anticoagulants, for any reasons DESPITE therapeutic anticoagulation as a treatment for Covid-19 patients.
* Recent (less than 1 month) chemotherapy
* Active inflammatory disease
* Haemophilia and other coagulopathy
* Previous history of thrombocytopenia (\<100 000 platelets/mm3)
* Cirrhosis (Child Plug \> A)
* Recent (less than 48 hours) major surgery
Exclusion criteria for Covid-19 patients:
\- bacterial co-infection